Dr. Antonio Lee

Dr. Antonio (Tony) Lee is the Global President & Executive Director of MEDIPOST Korea and serves as the Co-CEO of MEDIPOST Inc. (U.S.) and CEO of MEDIPOST K.K. (Japan), the wholly owned U.S. and Japanese subsidiaries of MEDIPOST, respectively. After earning his BSc (Hons) and MSc in Human Anatomy & Structural Biology and a PhD in Developmental Biology from the University of Otago in New Zealand, Dr. Lee held research positions in translational and regenerative medicine at the University of Sydney and the University of New South Wales, Australia. 

Since joining MEDIPOST in 2011, Dr. Lee has led the company’s global commercialization and clinical development strategy for human umbilical cord blood-derived mesenchymal stem/stromal cell (hUCB-MSC) technologies and products, including the world’s first regulatory-approved allogeneic MSC product, CARTISTEM®, for knee osteoarthritis. He has overseen late-stage clinical trials in Japan and the U.S., and commercial manufacturing, CMC, and market access strategies across multiple jurisdictions, with over 33,000 patients treated with CARTISTEM® in South Korea since its market launch in 2012.